These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12823686)

  • 1. Are thiazide diuretics preferred as first-line therapy for hypertension? An appraisal of The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Scott I; Stowasser M
    Intern Med J; 2003 Jul; 33(7):327-30. PubMed ID: 12823686
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
    Rahman M; Ford CE; Cutler JA; Davis BR; Piller LB; Whelton PK; Wright JT; Barzilay JI; Brown CD; Colon PJ; Fine LJ; Grimm RH; Gupta AK; Baimbridge C; Haywood LJ; Henriquez MA; Ilamaythi E; Oparil S; Preston R;
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):989-1002. PubMed ID: 22490878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].
    Kuwajima I
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():648-53. PubMed ID: 15171450
    [No Abstract]   [Full Text] [Related]  

  • 4. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
    Oparil S; Davis BR; Cushman WC; Ford CE; Furberg CD; Habib GB; Haywood LJ; Margolis K; Probstfield JL; Whelton PK; Wright JT;
    Hypertension; 2013 May; 61(5):977-86. PubMed ID: 23529173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J;
    Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALLHAT, or the soft science of the secondary end point.
    Messerli FH
    Ann Intern Med; 2003 Nov; 139(9):777-80. PubMed ID: 14597462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R;
    Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ALLHAT Trial. Diuretics are still the preferred initial drugs for high blood pressure.
    Vidt DG
    Cleve Clin J Med; 2003 Mar; 70(3):263-9. PubMed ID: 12678218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic issues in the Antihypertensive and Lipid-Lowering Heart Attack Trial Study.
    Punzi HA; Punzi CF; ;
    Curr Hypertens Rep; 2004 Apr; 6(2):106-10. PubMed ID: 15010012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.
    Yamal JM; Oparil S; Davis BR; Alderman MH; Calhoun DA; Cushman WC; Fendley HF; Franklin SS; Habib GB; Pressel SL; Probstfield JL; Sastrasinh S;
    J Am Soc Hypertens; 2014 Nov; 8(11):808-19. PubMed ID: 25455006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Black HR; Davis B; Barzilay J; Nwachuku C; Baimbridge C; Marginean H; Wright JT; Basile J; Wong ND; Whelton P; Dart RA; Thadani U;
    Diabetes Care; 2008 Feb; 31(2):353-60. PubMed ID: 18000186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidelines for antihypertensive treatment: an update after the ALLHAT study.
    Salvetti A; Ghiadoni L
    J Am Soc Nephrol; 2004 Jan; 15 Suppl 1():S51-4. PubMed ID: 14684673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
    Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
    Pharmacogenet Genomics; 2009 Jun; 19(6):415-21. PubMed ID: 19352213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Established blood pressure drug wins out in a comparative study. In hypertension, a diuretic first!].
    Wepner U
    MMW Fortschr Med; 2003 Jan; 145(1-2):10-2. PubMed ID: 12638431
    [No Abstract]   [Full Text] [Related]  

  • 17. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
    Einhorn PT; Davis BR; Massie BM; Cushman WC; Piller LB; Simpson LM; Levy D; Nwachuku CE; Black HR;
    Am Heart J; 2007 Jan; 153(1):42-53. PubMed ID: 17174636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
    Dewland TA; Soliman EZ; Yamal JM; Davis BR; Alonso A; Albert CM; Simpson LM; Haywood LJ; Marcus GM
    Circ Arrhythm Electrophysiol; 2017 Dec; 10(12):. PubMed ID: 29212812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Heidenreich PA; Davis BR; Cutler JA; Furberg CD; Lairson DR; Shlipak MG; Pressel SL; Nwachuku C; Goldman L
    J Gen Intern Med; 2008 May; 23(5):509-16. PubMed ID: 18228109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
    Alderman MH; Piller LB; Ford CE; Probstfield JL; Oparil S; Cushman WC; Einhorn PT; Franklin SS; Papademetriou V; Ong ST; Eckfeldt JH; Furberg CD; Calhoun DA; Davis BR;
    Hypertension; 2012 May; 59(5):926-33. PubMed ID: 22431578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.